CannAssure Therapeutics

Cannassure develops and commercializes a wide range of effective, high-quality, affordable medical cannabis products and pharmaceutical cannabinoid medicines designed to enhance treatment and improve the quality of life for people worldwide. The company ensures the highest standards by facilitating a holistic integrated production system, including a clean and controlled and advanced indoor aeroponic grow facility and an extraction and processing facility, along with scientifically advanced research and development. Cannassure operates in accordance with IMC-GAP standards, testing both its unprocessed cultivated cannabis and its manufactured products at different stages of production to ensuring purity, effectiveness, stability, and consistency for the duration of the products shelf life. Cannasure is a spinoff of food manufacturer Solbar Food Technologies, with 60 years of applied industrial expertise and know-how. Solbar is the majority shareholder in the company.

CannAssure Therapeutics has raised $3.44M in total funding across 2 rounds. The company is currently at the Public stage.

CannAssure Therapeutics was founded in 2016 by Nir Peles (Founder & Board Member ).

CannAssure Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Medical Cannabis, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients.

CannAssure Therapeutics is based in HaHadarim Street 2, Ashdod, Israel, South District.